Literature DB >> 9496833

Absence of detectable EWS/FLI1 expression after therapy-induced neural differentiation in Ewing sarcoma.

S R Knezevich1, G Hendson, J A Mathers, B Carpenter, D Lopez-Terrada, K L Brown, P H Sorensen.   

Abstract

Ewing sarcoma and other peripheral primitive neuroectodermal tumors (pPNETs) display limited neural differentiation and are thought to have a neural crest origin Greater than 95% of these tumors share common t(11;22)(q24;q12) ort(21;22)(q22;q12) chromosomal translocations leading to ES/FLI1 or EWS/ERG gene fusions, respectively. The resulting chimeric oncoproteins seem to function as aberrant transcription factors. However, whether these molecules contribute to the limited neural differentiation observed in pPNETs or actually inhibit differentiation remains unclear. We report a Ewing sarcoma case from the forearm of a 10-year-old girl which expressed EWS/FLI1 fusion transcripts. The tumor was treated with surgery, chemotherapy, and local radiation, but residual tumor was detected within a year as a well-differentiated peripheral neural tumor lacking detectable EWS/FLI1 expression. Further studies suggested that the primary and residual tumors were clonally related. This association between apparent therapy-induced differentiation in Ewing sarcoma and absence of detectable fusion transcripts in the residual tumor provides presumptive evidence that EWS/FLI1 expression may inhibit differentiation in tumour cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9496833     DOI: 10.1016/s0046-8177(98)90049-1

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  Pathobiologic markers of the ewing sarcoma family of tumors: state of the art and prediction of behaviour.

Authors:  Alfredo Pinto; Paul Dickman; David Parham
Journal:  Sarcoma       Date:  2010-10-14

2.  Modeling initiation of Ewing sarcoma in human neural crest cells.

Authors:  Cornelia von Levetzow; Xiaohua Jiang; Ynnez Gwye; Gregor von Levetzow; Long Hung; Aaron Cooper; Jessie Hao-Ru Hsu; Elizabeth R Lawlor
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

Review 3.  The potential for molecular therapeutic targets in Ewing's sarcoma.

Authors:  Nancy R McAllister; Stephen L Lessnick
Journal:  Curr Treat Options Oncol       Date:  2005-11

4.  Trk inhibition reduces cell proliferation and potentiates the effects of chemotherapeutic agents in Ewing sarcoma.

Authors:  Tiago Elias Heinen; Rafael Pereira Dos Santos; Amanda da Rocha; Michel Pinheiro Dos Santos; Patrícia Luciana da Costa Lopez; Marco Aurélio Silva Filho; Bárbara Kunzler Souza; Luís Fernando da Rosa Rivero; Ricardo Gehrke Becker; Lauro José Gregianin; Algemir Lunardi Brunetto; André Tesainer Brunetto; Caroline Brunetto de Farias; Rafael Roesler
Journal:  Oncotarget       Date:  2016-06-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.